Shiseido (OTCMKTS:SSDOY) and Imprimis Pharmaceuticals (NASDAQ:IMMY) are both consumer staples companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Shiseido and Imprimis Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shiseido 0 0 0 0 N/A
Imprimis Pharmaceuticals 0 0 2 0 3.00

Imprimis Pharmaceuticals has a consensus price target of $10.75, indicating a potential upside of ∞. Given Imprimis Pharmaceuticals’ higher probable upside, analysts plainly believe Imprimis Pharmaceuticals is more favorable than Shiseido.

Institutional & Insider Ownership

16.1% of Imprimis Pharmaceuticals shares are held by institutional investors. 13.8% of Imprimis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Shiseido has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Imprimis Pharmaceuticals has a beta of -1.06, indicating that its share price is 206% less volatile than the S&P 500.


Shiseido pays an annual dividend of $0.36 per share and has a dividend yield of 0.5%. Imprimis Pharmaceuticals does not pay a dividend. Shiseido pays out 23.8% of its earnings in the form of a dividend.


This table compares Shiseido and Imprimis Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Shiseido 5.67% 14.10% 6.89%
Imprimis Pharmaceuticals -16.81% -231.16% -25.18%

Earnings and Valuation

This table compares Shiseido and Imprimis Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Shiseido $9.92 billion N/A $558.78 million $1.51 49.61
Imprimis Pharmaceuticals $26.77 million 0.00 -$11.98 million ($0.60) N/A

Shiseido has higher revenue and earnings than Imprimis Pharmaceuticals. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.


Shiseido beats Imprimis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Shiseido

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. It also produces and sells health and beauty foods, and over-the-counter drugs; and hair and beauty salon products, as well as fragrances and body care products. In addition, the company operates beauty salons and restaurants. Further, it produces and sells cosmetic raw materials, medical-use drugs, medical cosmetics, and precision and analytical equipment. The company sells its products through cosmetic stores, department stores, mass merchandising stores, drug stores, and perfumeries. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive News & Ratings for Shiseido Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shiseido and related companies with's FREE daily email newsletter.